PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Drug Users”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources
PubMed2004

Bangkok 2004. Double discrimination: drug users living with HIV/AIDS.

Drug users in Russia living with HIV/AIDS are often denied basic medical and social services and are systematically excluded from antiretroviral therapy programs. In this presentation to "HIV Treatment for Drug Users--A Realistic Goal," a satellite meeting of the XIV International AIDS Conference held on 15 July 2004, Dmitry Samoilov describes the discrimination faced by people living with HIV/AIDS in general, and HIV-positive drug users in particular. The presentation includes powerful personal testimonials from people living with HIV/AIDS. The author describes the obstacles to drug users' accessing health care, and concludes with suggestions for actions that should be taken to address the problem.

HIV Infections↗
PubMed2004

Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.

Rising pharmaceutical expenditures have led to the use of cost-sharing measures. The authors undertook a systematic review of the effects of cost sharing on vulnerable populations (the poor and those with chronic illnesses). Virtually every article reviewed supports the view that cost sharing decreases the use of prescription drugs in these populations. Copayments or a cap on the monthly number of subsidized prescriptions lower drug costs for the payer, but any savings may be offset by increases in other health care areas. Cost sharing also leads to patients foregoing essential medications and to a decline in health care status.

Chronic Disease↗
PubMed2006

Variations in drug users' accounts of the connection between drug misuse and crime.

A great deal of progress has been made in identifying explanations for the links between drug use and crime. However, less progress has been made in the application of these explanations. In particular, less is known about whether some explanations are more common than others, whether some are linked to certain conditions, whether some apply only to certain individuals, and whether some apply only to certain kinds of drug use and crime. In this article, we investigate the extent to which explanations for the connection between drug misuse and crime vary by type of drug user, type of drug use and type of crime by looking at users' own accounts of the connection. The research is based on data collected as part of the New English and Welsh Arrestee Drug Abuse Monitoring (NEW-ADAM) program conducted in 16 custody suites in England and Wales. The analysis investigates the proportion of drug users who believe that there is a connection and looks at variations in accounts of the connection by individual and behavioral factors. The implications for government policy designed to reduce drug-related crime are discussed.

Adolescent↗
PubMed2001

Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment.

AIMS: To assess prevalence of, and behavioural risk factors for, hepatitis B and C in drug users both in and out of contact with drugs services. DESIGN: Cross-sectional survey of hepatitis B and C prevalence using blood samples and self-completed risk factor questionnaires. PARTICIPANTS: Three hundred and sixty injecting drug users (IDUs) in treatment for their drug use, attending syringe exchange schemes (SES), and not in contact with any services in Wirral and Manchester between 1997 and 1999, for whom test results were available for 334 (hepatitis B) and 341 (hepatitis C). FINDINGS: Hepatitis B prevalence differed between groups, from 19% of those not in contact to 41% of those presenting to request a test (p = 0.040). Prevalence of hepatitis C ranged from 48% (SES) to 62% among those presenting for a test (p = 0.233). After multivariate adjustment, hepatitis B was predicted by prison stays (p = 0.030) and injecting for longer (p = 0.003). For hepatitis C, length of injecting career (p = 0.036), having been to prison (p = 0.034), having injected more than one drug type (p < 0.001) and being female (p = 0.037) predicted infection. Overall, 38% had shared some form of injecting equipment in the previous 4 weeks. People recently starting injecting were more likely to share, and sharing was more likely to occur when injecting with only one other user rather than in larger groups. Those who had previously presented for a hepatitis C test, regardless of the result, were less likely to have recently shared injecting equipment. CONCLUSIONS: Behaviours associated with transmission of hepatitis B and C are common among IDUs. In particular, sharing of injecting equipment was more likely in small groups and in those recently beginning injecting. More broadly, chaotic drug use and time in prison were also risk factors for hepatitis infections. When assessing prevalence of hepatitis B and C, our results suggest that figures cannot be extrapolated from those in service contact to those in the wider drug-using population.

Adult↗
PubMed1991

Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users.

To investigate whether drug use affected immunological parameters, we conducted a cross-sectional study of 321 drug users. Absolute numbers of CD4+ lymphocytes and the T-cell reactivity were lower in HIV-positive than in HIV-negative people. The functional capacity of the T-cell system as measured after stimulation with a monoclonal antibody directed against CD3 was found to be strongly associated with the frequency of injecting, while no relationship was found between the frequency of injecting and the total number of lymphocytes or T-cell subsets. HIV-negative and HIV-positive drug users who had injected a mean of three times a day in the preceding 4-6 months had a T-cell reactivity which was 40-50% lower compared with seronegative and with seropositive drug users who had not injected in the preceding months. We conclude that lymphocyte reactivity is depressed by frequent injecting in HIV-negative and HIV-positive drug users.

Adult↗
PubMed1992

Characteristics of intravenous drug users by history of arrest and treatment for drug use.

Typically, intravenous drug users are studied by drawing samples from drug treatment programs, from the criminal justice system, or by outreach into the street community via anthropological or ethnographic methods. Among 1405 subjects recruited through extensive community outreach, 46% reported no history of treatment for drug abuse and 16% said they had not been arrested in the preceding 10 years; 130 (9%) reported neither history. A history of arrest was higher among men and those with a history of: treatment for drug abuse, low educational attainment, having received public assistance, and unemployment. A history of drug treatment was higher among women and those of an older age with a history of: arrest, having received public assistance, and a greater duration and intensity of intravenous drug use. Intravenous drug users who had neither a history of arrest since 1977 nor of drug treatment were more likely to be women and more educated, to have not received public assistance, and to inject less than weekly. These data indicate that characteristics of intravenous drug users differ by history of arrest and treatment, substantiating reports of heterogeneity among intravenous drug users.

Black or African American↗
PubMed1993

HIV risk behaviors and HIV seropositivity among young injection drug users.

Although injection drug use (IDU) is the major risk category for HIV infection in Puerto Rico and injection drug users start their drug injection careers very young, there is little information related to drug injection patterns of young IDUs. In this paper we report on factors found to be associated with HIV seropositivity among 255 young IDUs (16-24 years old). Overall, 23.5% subjects were HIV seropositive. Being 22 to 24 years old, having dropped out of school, having a history of incarceration, and having been diagnosed with STDs, and initiating drug use injection before 17 years of age were the factors significantly related to HIV seropositivity. Findings suggest that prevention programs should begin early in the development of youngsters. Special HIV and STD preventive programs for youngsters at risk of leaving school before completing high school should be a priority.

Adolescent↗
PubMed1992

Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. The Northern Italian Seronegative Drug Addicts (NISDA) Study.

To evaluate the role of parenteral and sexual transmission of human immunodeficiency virus, we studied seronegative intravenous drug users recruited from 25 drug dependence treatment centers in northern Italy. All attending intravenous drug users were asked for their consent and screened for antibodies to human immunodeficiency virus; those who were seronegative were enrolled, interviewed about their habits, and invited to follow-up visits. Between 1987 and 1989, 1,195 seronegative intravenous drug users were enrolled, 635 were followed up (mean duration, 11.9 months), and 35 seroconversions were observed. The incidence rate ratios were 3.3 (95% confidence interval (CI) 1.4-7.5) for subjects aged less than 20 years, 2.4 (95% CI 1.2-4.7) for less than 2 years of intravenous drug use, 2.2 (95% CI 0.9-5.5) for syringe sharing, and 1.0 for subjects with a sexual partner who had tested positive for human immunodeficiency virus. A case-control approach, using logistic regression and adjusting for sex, age, area, and prevalence, showed odds ratios of 13.2 (95% CI 3.1-56.8) for frequent syringe sharing and 4.0 (95% CI 1.5-10.4) for sexual contacts with seropositive partners; frequent use of condoms was associated with a reduction in risk that did not reach statistical significance. Parenteral transmission is the most important route of infection with the human immunodeficiency virus among intravenous drug users, and sexual transmission plays a relevant, additive role.

Adult↗
PubMed2005

Getting global funds to those most in need: the Thai Drug Users' Network.

The Thai Drug Users' Network (TDN) formed in 2002 in response to the deplorable health and human rights conditions facing illicit drug users in Thailand. In 2003, TDN submitted a proposal for funding to the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM). The proposal appeared destined to fail as it did not have the support of the Thai government and because the interventions proposed were highly incongruent with national policies. In the midst of an ongoing drug war, TDN took action to increase awareness of the harms of the drug war, the shortcomings in GFATM policies, and the need for peer-driven interventions. This article describes the circumstances surrounding this instance of successful drug-user organizing in order to identify the lessons that can be learned.

Financing, Organized↗
PubMed1999

Prevalence of Mycobacterium tuberculosis infection among injection drug users in Toronto.

BACKGROUND: Injection drug users are at increased risk of Mycobacterium tuberculosis infection and active tuberculosis (TB). The primary objective of this study was to determine the prevalence of M. tuberculosis infection among injection drug users in Toronto, as indicated by a positive tuberculin skin test result. An additional objective was to identify predictors of a positive skin test result in this population. METHODS: A cross-sectional study was carried out involving self-selected injection drug users in the city of Toronto. A total of 171 participants were recruited through a downtown Toronto needle-exchange program from June 1 to Oct. 31, 1996. RESULTS: Of 167 subjects tested, 155 (92.8%) returned for interpretation of their skin test result within the designated timeframe (48 to 72 hours). Using a 5-mm cut-off, the prevalence rate of positive tuberculin skin test results was 31.0% (95% confidence interval 23.8% to 38.9%). Birth outside of Canada and increasing age were both predictive of a positive result. INTERPRETATION: There is a high burden of M. tuberculosis infection in this population of injection drug users. The compliance observed with returning for interpretation of skin test results indicates that successful TB screening is possible among injection drug users.

Adult↗
PubMed1987

AIDS--risk behaviours and AIDS knowledge in intravenous drug users.

Surveys of intravenous drug users were undertaken in July 1985 and one year later to assess behaviours which could result in risk of HIV infection and transmission. Ready availability of sterile syringes was reported by 48% in 1986 and 63% in 1985. Sharing of syringes amongst intravenous drug users is a common practice. In 1986, 22% of subjects reported no sharing of syringes, 16% sharing with one and 62% with between 2 and 20 others. There was a significant trend towards less sharing, and improved sterilisation of syringes in 1986. Nearly all subjects were aware of the risks of HIV transmission via shared syringes. In 1985, 19% of subjects reported adopting safer-sex practices compared with 28% in 1986. A history of prostitution was reported by 50% of women. All subjects were aware intravenous drug users had been asked not to donate blood, and none reported having done so within five years. All the subjects tested for HIV antibody were negative.

Acquired Immunodeficiency Syndrome↗
PubMed2002

Predictive validity of a measure of treatment readiness for out-of-treatment drug users: enhancing prediction beyond demographic and drug history variables.

The predictive validity of a treatment readiness measure designed for out-of-treatment drug users, tapping dimensions of perceived problem severity, perceived need for formal treatment, motivation for treatment, and negative attitudes toward treatment is examined using data from a National Institute on Drug Abuse (NIDA)-funded HIV outreach intervention in San Antonio, Texas. Logistic regression is used to predict use of substance abuse treatment services three months after program intake on the basis of readiness scores, controlling for demographic and drug history variables. Analyses of data from 673 drug users in an HIV outreach intervention indicated that treatment readiness dimensions accounted for a 12% increase in variation in "use of any modality" and 14% for "use or attempted service use". Only Motivation to Quit was a significant predictor of "use of any modality" and both Perceived Need for Treatment and Motivation to Quit were significant predictors of "use or attempted use". Findings support the importance of the individual's perception of "readiness" to change their substance-abusing behavior and enter treatment.

Adult↗
PubMed1997

Sequence of drug use among serious drug users: typical vs atypical progression.

Sequence of drug use was examined in a secondary analysis of two samples of serious drug users: one of 152 men and one of 133 women. The proportions of drug users following specified patterns of drug use onset were compared to proportions obtained in previous research in samples of high school youth, and serious drug users. The serious drug users were substantially different from high school samples in their progression of drug use. The serious drug users were less likely to follow the typical sequence identified in previous studies (alcohol, then marijuana, followed by other illicit drugs). They were more likely to have used marijuana before using alcohol, and more likely to have used other illicit drugs before using marijuana. We also found that atypical sequencing was associated with earlier initiation of the use of illicit drugs other than marijuana and greater lifetime drug involvement. These findings suggest that for a large number of serious drug users, marijuana does not play the role of a 'gateway drug'. We conclude that prevention efforts which focus on alcohol and marijuana may be of limited effectiveness for youth who are at risk for serious drug abuse.

Adult↗
PubMed2006

Stigma, discrimination and the health of illicit drug users.

Persons who use illicit drugs are stigmatized in the United States. The conferral of a deviant social status on illicit drug users may serve to discourage use. However, stigmatization may also adversely affect the health of those who use illicit drugs, through exposure to chronic stress such as discrimination and as a barrier to accessing care. We hypothesized that aspects of stigma and discrimination would be associated with mental and physical health among illicit drug users. Using street outreach techniques, 1008 illicit drug users were interviewed about stigma and discrimination related to their drug use, and their health. We measured discrimination related to drug use, alienation, perceived devaluation, and responses to discrimination and stigma. Health measures included mental and physical health measures from the Medical Outcomes Study Short Form-36, depression symptoms from the Center for Epidemiological Studies Depression scale, and a sum of health conditions. In adjusted models, discrimination and alienation were both associated with poorer mental health, and only discrimination was associated with poorer physical health. Angry responses to discrimination and stigma were associated with poorer mental health. The association of stigma and discrimination with poor health among drug users suggests the need for debate on the relative risks and benefits of stigma and discrimination in this context.

Adolescent↗